- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04734587
Evaluation of Brain Damage Due to Coronary Angioplasty in Percutaneous Intervention Patients
September 29, 2021 updated by: Muhammet Uyanik, Ondokuz Mayıs University
Assessment of Silent Brain Injury in Chronic Total Occlusion Patients With Percutaneous Coronary Intervention
This study examines the formation mechanism and patient-related factors of silent cerebral infarcts, whose importance has become increasingly recognized in patients undergoing percutaneous coronary intervention.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
This study was produced from the assistant's thesis and was previously accepted as a poster at EuroPCR 2020. We recently completed the full-length article.
This thesis study was supported by Ondokuzmayis University.
Study Type
Observational
Enrollment (Actual)
120
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Samsun, Turkey
- Ondokuzmayis University
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 80 years (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Probability Sample
Study Population
Patients who were planned to have revascularization due to CTO in at least one coronary artery (CTO Group) and patients who were scheduled for single-vessel elective coronary intervention other than CTO were defined as Non-CTO (control group).
Description
Inclusion Criteria:
- CTO and Non-CTO patients undergoing percutaneous coronary intervention
Exclusion Criteria:
- baseline NSE elevation
- acute coronary syndromes or cardiac surgery within 4 weeks
- patients with a cerebrovascular accident
- intracranial hemorrhage
- and head trauma
- central nervous system tumor
- degenerative central nervous system disorders and neuroendocrine tumors
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Chronic Total Occlusion
Chronic total occlusion patients undergoing percutaneous coronary intervention.
|
The Silent Brain Injury ratio was compared by measuring the Neuron-specific enzyme level with venous blood sampling from both patient groups before and after percutaneous coronary intervention.
|
Non-Chronic Total Occlusion
Non-Chronic total occlusion patients undergoing percutaneous coronary intervention.
|
The Silent Brain Injury ratio was compared by measuring the Neuron-specific enzyme level with venous blood sampling from both patient groups before and after percutaneous coronary intervention.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Baseline Neuron-specific Enolase (NSE) measurement
Time Frame: NSE blood levels were measured 1-2 hours before the procedure.
|
Baseline NSE measurement to exclude non-PCI dependent brain injury.
Elevation of >20 ng/ml was considered as silent brain injury.
Patients with basal nse elevation were considered as SBI and excluded from the study.
|
NSE blood levels were measured 1-2 hours before the procedure.
|
Silent Brain Injury diagnosis
Time Frame: 12-18 hours after percutaneous coronary intervention
|
NSE blood levels were measured 12-18 hours after the procedure.
Elevation of >20 ng/ml was considered as SBI.
|
12-18 hours after percutaneous coronary intervention
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Muhammet Uyanık, M.D., Ondokuz Mayıs University
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
January 18, 2019
Primary Completion (ACTUAL)
March 25, 2020
Study Completion (ACTUAL)
March 25, 2020
Study Registration Dates
First Submitted
January 23, 2021
First Submitted That Met QC Criteria
February 1, 2021
First Posted (ACTUAL)
February 2, 2021
Study Record Updates
Last Update Posted (ACTUAL)
October 6, 2021
Last Update Submitted That Met QC Criteria
September 29, 2021
Last Verified
September 1, 2021
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- SBI IN CTO INTERVENTION
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
UNDECIDED
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Coronary Disease
-
Peking Union Medical College HospitalNot yet recruitingCoronary Artery Disease | Inflammation | Coronary Artery Disease Progression | Coronary Artery Stenosis | Coronary Artery Restenosis | Inflammatory Disease | Inflammation VascularChina
-
Peking Union Medical College HospitalRecruitingCoronary Artery Disease | Inflammation | Coronary Artery Disease Progression | Coronary Artery Stenosis | Coronary Artery Restenosis | Inflammatory Disease | Inflammation VascularChina
-
Fundación EPICActive, not recruitingCoronary Artery Disease | Left Main Coronary Artery Disease | Left Main Coronary Artery Stenosis | Restenosis, CoronarySpain
-
Peking University Third HospitalCompletedCoronary Microvascular Dysfunction | Obstructive Coronary Heart DiseaseChina
-
Centro de estudios en Cardiologia IntervencionistaCompletedCoronary Heart Disease | Coronary RestenosisArgentina
-
Seung-Jung ParkCardioVascular Research Foundation, KoreaRecruitingCoronary Stenosis | Coronary Artery Bypass Grafting | Coronary Artery Disease Progression | Percutaneous Coronary RevascularizationKorea, Republic of
-
Istanbul UniversityCompletedIschemic Heart Disease | Coronary Microvascular Disease | Microvascular Angina | Coronary Microvascular Dysfunction | Non-Obstructive Coronary Atherosclerosis | Microvascular Coronary Artery DiseaseTurkey
-
Deutsches Herzzentrum MuenchenCompletedCoronary Heart DiseaseGermany
-
National Institutes of Health Clinical Center (CC)National Heart, Lung, and Blood Institute (NHLBI)CompletedCoronary Arteriosclerosis | Coronary Artery Disease (CAD) | Obstructive Coronary Artery DiseaseUnited States
-
National Heart Centre SingaporeUnknownCoronary Heart DiseaseSingapore
Clinical Trials on Blood serum Neuron-specific Enolase measurement
-
First Affiliated Hospital Xi'an Jiaotong UniversityXi'an Central Hospital; Shaanxi Provincial People's Hospital; Second Affiliated... and other collaboratorsUnknown
-
Rabin Medical CenterUnknownPhosphopyruvate HydrataseIsrael
-
Lithuanian University of Health SciencesResearch Council of LithuaniaCompletedNewborn, Infant, Disease | Peri-operative InjuryLithuania
-
Ege UniversityCompletedPostoperative Cognitive Dysfunction | Brain Damage | Neuron Specific Enolase | Glial Fibrillary Acidic ProteinTurkey
-
Akdeniz UniversityCompletedNeurologic Manifestations | Kidney Transplant; Complications | Uremic EncephalopathyTurkey
-
Bora DincCompleted
-
Benha UniversityCompleted
-
Zagazig UniversityCompleted
-
Akdeniz UniversityRecruitingBrain Damage | Postoperative | Surgery-ComplicationsTurkey
-
Assiut UniversityNot yet recruitingGalectin-3 and Pemphigus